OBJECTIVES: To examine priorities for health status improvement in patients with active rheumatoid arthritis (RA) during anti-tumour necrosis factor (TNF) treatment. METHODS: Data were used from 173 patients with RA starting treatment with TNF-blocking agents. Outcome measures included assessment of health status with the Arthritis Impact Measurement Scales 2 (AIMS2) at baseline and after 3 and 12 months. The AIMS2 contains a priority list from which patients are asked to select from 12 areas of health the 3 in which they would most like to see improvement. RESULTS: After 1 year of treatment, 10 out of 12 areas of health on the AIMS2 were significantly improved. The most commonly selected priorities for improvement at baseline were pain (88...
Reaching the therapeutic target of remission or low-disease activity has improved outcomes in patien...
Objective To evaluate changes in baseline patient characteristics and entry criteria of randomised, ...
Objectives: To describe changes in health-related quality of life (HRQoL) up to 60 months after comm...
Objectives: To examine priorities for health status improvement in patients with active rheumatoid a...
Contains fulltext : 53171.pdf (publisher's version ) (Closed access)OBJECTIVES: To...
PURPOSE: To investigate the priorities for health status improvement of patients with active rheumat...
OBJECTIVES: To compare the health priorities elected by patients with rheumatic diseases and by thei...
Objective. Function, patient global assessment, and pain are routinely measured in rheumatoid arthri...
OBJECTIVES: Rheumatoid arthritis (RA) patients with moderate disease activity show progression of j...
OBJECTIVES: Rheumatoid arthritis (RA) patients with moderate disease activity show progression of j...
Background: Anti-Tumor Necrosis Factor alpha (anti-TNF) drugs markedly improved the therapeutic appr...
OBJECTIVE: Reduced work participation (WP) is a common problem for patients with rheumatoid arthriti...
Objectives: This retrospective study used various indices to evaluate remission and low disease acti...
Objective: To determine the prevalence of minimal disease activity (MDA) and remission in patients w...
Objective: To study transitions from and to chronic widespread pain (CWP) over 7 years in patients w...
Reaching the therapeutic target of remission or low-disease activity has improved outcomes in patien...
Objective To evaluate changes in baseline patient characteristics and entry criteria of randomised, ...
Objectives: To describe changes in health-related quality of life (HRQoL) up to 60 months after comm...
Objectives: To examine priorities for health status improvement in patients with active rheumatoid a...
Contains fulltext : 53171.pdf (publisher's version ) (Closed access)OBJECTIVES: To...
PURPOSE: To investigate the priorities for health status improvement of patients with active rheumat...
OBJECTIVES: To compare the health priorities elected by patients with rheumatic diseases and by thei...
Objective. Function, patient global assessment, and pain are routinely measured in rheumatoid arthri...
OBJECTIVES: Rheumatoid arthritis (RA) patients with moderate disease activity show progression of j...
OBJECTIVES: Rheumatoid arthritis (RA) patients with moderate disease activity show progression of j...
Background: Anti-Tumor Necrosis Factor alpha (anti-TNF) drugs markedly improved the therapeutic appr...
OBJECTIVE: Reduced work participation (WP) is a common problem for patients with rheumatoid arthriti...
Objectives: This retrospective study used various indices to evaluate remission and low disease acti...
Objective: To determine the prevalence of minimal disease activity (MDA) and remission in patients w...
Objective: To study transitions from and to chronic widespread pain (CWP) over 7 years in patients w...
Reaching the therapeutic target of remission or low-disease activity has improved outcomes in patien...
Objective To evaluate changes in baseline patient characteristics and entry criteria of randomised, ...
Objectives: To describe changes in health-related quality of life (HRQoL) up to 60 months after comm...